- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 3,25 $ / 3,32 $ |
| Spread | +2,15% |
| Schluss Vortag | 3,47 $ |
| Gehandelte Stücke | 2.719 |
| Tagesvolumen Vortag | 65.049,65 $ |
| Tagestief 3,21 $ Tageshoch 3,45 $ | |
| 52W-Tief 3,15 $ 52W-Hoch 7,05 $ | |
| Jahrestief 3,15 $ Jahreshoch 7,05 $ | |
| Umsatz in Mio. | 7,70 $ |
| Operatives Ergebnis (EBIT) in Mio. | -34,63 $ |
| Jahresüberschuss in Mio. | -33,38 $ |
| Umsatz je Aktie | 4,12 $ |
| Gewinn je Aktie | -17,85 $ |
| Gewinnrendite | -433,74% |
| Umsatzrendite | -433,74% |
| Return on Investment | -58,81% |
| Marktkapitalisierung in Mio. | 7,67 $ |
| KGV (Kurs/Gewinn) | -0,31 |
| KBV (Kurs/Buchwert) | 0,39 |
| KUV (Kurs/Umsatz) | 1,33 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +46,71% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| AMEX | 4,78 $ | - | - | 22.05.26 | |
| Frankfurt | 0,259 € | 0 % | 0,259 € | 06.06.25 | |
| München | 0,26 € | -3,06% | 0,2682 € | 06.06.25 | |
| Nasdaq | 3,31 $ | -4,61% | 3,47 $ | 20:26 | |
| NYSE | 4,04 $ | 0 % | 4,04 $ | 10.08.26 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 12.08.26 | 3,45 | 65 T |
| 11.08.26 | 3,98 | 2.161 |
| 10.08.26 | 3,97 | 3.068 |
| 07.08.26 | 4,05 | 6.732 |
| 06.08.26 | 3,87 | 28.759 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 3,87 $ | -10,34% |
| 1 Monat | 3,78 $ | -8,20% |
| 6 Monate | 4,95 $ | -29,90% |
| 1 Jahr | 5,62 $ | -38,26% |
| 5 Jahre | - | - |
| Marktkapitalisierung | 7,67 Mio. $ |
| Streubesitz | 92,19% |
| Währung | USD |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +7,17% | Sofinnova Ventures |
| +4,02% | Renaissance Technologies Corp |
| +3,77% | Vivo Capital, LLC |
| +2,22% | Pivotal bioVenture Partners Investment Advisor LLC |
| +1,98% | T3 Companies, LLC |
| +1,87% | Board of Ttees Leland Stanford Jr Univ |
| +1,63% | Pfizer Inc |
| +1,60% | Lynx1 Capital Management, LP |
| +1,52% | Nan Fung Group Holdings Ltd |
| +1,50% | Geode Capital Management, LLC |
| +1,43% | NANO CAP NEW MILLENNIUM GROWTH FUND L P |
| +0,89% | Fidelity Extended Market Index |
| +0,78% | Shay Capital LLC |
| +0,61% | Susquehanna International Group, LLP |
| +0,53% | Citadel Advisors Llc |
| +0,51% | BlackRock Inc |
| +0,37% | Vanguard Institutional Extnd Mkt Idx Tr |
| +0,37% | Vanguard Capital Management, LLC |
| +0,28% | Fidelity Total Market Index |
| +0,17% | Spartan Extended Market Index Pool F |
| +0,17% | Morgan Stanley - Brokerage Accounts |
| +0,16% | Vanguard Fiduciary Trust Co |
| +0,10% | NT Ext Eq Mkt Idx Fd DC Lending Tier 5 |
| +0,09% | Fidelity Series Total Market Index |
| +0,08% | Blackrock Extended Mkt Fund CF |
| +0,08% | Extended Equity Market Fund B |
| +0,08% | Extended Equity Market Fund E |
| +0,07% | Spartan Total Market Index Pool A1 |
| +0,07% | BlackRock Extended Equity Market Fund K |
| +0,07% | Spartan Total Market Index Pool G |
| +0,06% | NT Ext Equity Mkt Index Fund - NL |
| +0,06% | Tower Research Capital LLC |
| +0,05% | NT Ext Equity Mkt Idx Fd - DC - NL - T2 |
| +0,04% | UBS Group AG |
| +0,02% | Northern Trust Extended Eq Market Idx |
| +0,02% | NT Ext Equity Mkt Index Fund - Lending |
| +0,01% | State St US Extended Mkt Indx NL Cl C |
| +0,01% | BNYM Mellon SL Market Completion UC1 |
| +0,01% | Extended Equity Market Fund M |
| +0,01% | Fidelity Nasdaq Composite Index |
| 0,00% | State St US Ttl Mkt Idx NL Cl A |
| 0,00% | BlackRock Diversified Equity Alpha Inst |
| +28,87% | Institutionelle Aktionäre |
| +92,19% | Streubesitz |
| +63,32% | Individuelle Aktionäre |
Zahlen für Q3/23
- to fund key milestones through 2025
https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-reports-third-quarter-2023-financial
Von der Pipeline bin ich nicht sonderlich überzeugt, aber wer weiß vlt hebt die nächste Flut auch dieses Boot.
MK 39 Mio. $
https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-receives-orphan-drug-designation-bdc-1001
Zwar massiv unter Cash aber dafür auch ohne kurzfristige Katalysatoren.
Zahlen für Q2/23
- to fund key milestones through 2025
https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-reports-second-quarter-2023-financial
Zahlen für Q1/23
- to fund key clinical milestones through 2025
https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-reports-first-quarter-2023-financial